The FDA’s initiative signals a fundamental shift in clinical research, moving away from periodic data submissions toward a model of continuous, transparent oversight. EDETEK’s platform addresses this transition by unifying data capture, standardization, and governance within a single architecture. The system facilitates the delivery of pre-defined safety and efficacy signals to regulators as studies progress, ensuring that information remains review-ready and traceable throughout the development lifecycle.

"Real-time clinical trials represent one of the most meaningful shifts in how new medicines can be developed," said Jian Chen, CEO of EDETEK. The platform integrates human-supervised risk surveillance and anomaly detection through its BioStat.AI and Ensemble AI Managed Services. These tools operate under 21 CFR Part 11-compliant controls, allowing sponsors to monitor Key Risk Indicators and Quality Tolerance Limits in real-time. According to Dr. Shakthi Kumar, Chief Strategy & Business Officer, the model maintains a clear division of roles where the sponsor retains ownership of clinical strategy and FDA engagement, while EDETEK provides the validated infrastructure and AI-enabled discipline required by regulators. The platform is available immediately to global sponsors and biotechnology organizations.